Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.

Nature biotechnology - 1 Oct 2013

Themeli Maria, Kloss Christopher C, Ciriello Giovanni, Fedorov Victor D, Perna Fabiana, Gonen Mithat, Sadelain Michel

Abstract excerpt

Progress in adoptive T-cell therapy for cancer and infectious diseases is hampered by the lack of readily available, antigen-specific, human T lymphocytes. Pluripotent stem cells could provide an unlimited source of T lymphocytes, but the therapeutic potential of human pluripotent stem cell-deriv...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to Cell Differentiation
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cluster Analysis

Share to Induced Pluripotent Stem Cells

Share to Protein Engineering

Share to Receptors, Antigen

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 23934177
DOI: 10.1038/nbt.2678
PMCID: PMC5722218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23934177-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.PMID 23934177Read ↗

Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer ImmunotherapySemantic proximity Read ↗

Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cellsSemantic proximity Read ↗

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and ChallengesSemantic proximity Read ↗

Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and PerspectivesSemantic proximity Read ↗

Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer ImmunotherapySemantic proximity Read ↗

Induced Pluripotent Stem Cells Provide an Unlimited T-cell Source for CAR-T cell Development and A Potential Source for Off-the-shelf ProductsSemantic proximity Read ↗

Generation of CD34 <sup>+</sup> CD43 <sup>+</sup> hematopoietic progenitors to induce thymocytes from human pluripotent stem cellsSemantic proximity Read ↗

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospectsSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Engineered T cells from induced pluripotent stem cells: from research towards clinical implementationSemantic proximity Read ↗

Generation of CD34+CD43+ Hematopoietic Progenitors to Induce Thymocytes from Human Pluripotent Stem CellsSemantic proximity Read ↗

Pluripotent stem cell-based immunotherapy: advances in translational research, cell differentiation, and gene modificationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.